Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.66 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.66 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921694 | 0.86 | SLC22A12 (0.50) | CYP11B2CYP11B1SLC22A12RPS6KA3 | |
| SCHEMBL6922179 | 0.82 | CCNC (0.50) | CYP11B2CYP11B1CYP17A1SLC22A12RPS6KA3 | |
| SCHEMBL1769844 | 0.79 | CYP11B2 (0.64) | CYP11B2CYP11B1CYP17A1SLC22A12CYP1A2 | |
| SCHEMBL6920203 | 0.78 | CYP11B2 (0.44) | CYP11B2CYP11B1SLC22A12RPS6KA3ABL1 | |
| SCHEMBL6921971 | 0.78 | SLC22A12 (0.54) | CYP11B2CYP11B1SLC22A12RPS6KA3CYP3A4 | |
| SCHEMBL1769941 | 0.78 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP17A1SLC22A12ABL1 | |
| SCHEMBL14225083 | 0.77 | CYP11B1 (0.58) | CYP11B2CYP11B1SLC22A12RPS6KA3 | |
| SCHEMBL14225099 | 0.77 | SLC22A12 (0.55) | CYP11B2CYP11B1SLC22A12RPS6KA3ABL1 | |
| SCHEMBL1769849 | 0.75 | SLC22A12 (0.56) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL3068153 | 0.74 | SLC22A12 (0.50) | CYP11B2CYP11B1CYP17A1SLC22A12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | claimed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2501678-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885CYP17A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.